Φορτώνει......

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma

HER2+/ER+ breast cancer, a subset of the luminal B subtype, makes up approximately 10% of all breast cancers. The bidirectional crosstalk between HER2 and estrogen receptor (ER) in HER2+/ER+ breast cancer contributes to resistance towards both anti-estrogens and HER2-targeted therapies. TFF3 promote...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Oncotarget
Κύριοι συγγραφείς:	Chong, Qing-Yun, You, Ming-Liang, Pandey, Vijay, Banerjee, Arindam, Chen, Yi-Jun, Poh, Han-Ming, Zhang, Mengyi, Ma, Lan, Zhu, Tao, Basappa, Salundi, Liu, Liang, Lobie, Peter E.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Impact Journals LLC 2017
Θέματα:	Research Paper
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5650333/ https://ncbi.nlm.nih.gov/pubmed/29088778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18431
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma

Παρόμοια τεκμήρια